Who are Vectical Ointment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Calcijex, Calcitriol capsules, calcipotriol hydrate [Daivonex], Daivonex® scalp solution, Calcipotriene Foam, Calcipotriol BDP gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vectical-ointment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vectical Ointment — Competitive Intelligence Brief

Vectical Ointment (Vectical Ointment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D3 analog. Area: Dermatology.

marketed Vitamin D3 analog Vitamin D receptor (VDR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Vectical Ointment (Vectical Ointment) — University of California, San Francisco. Vectical is a topical vitamin D3 analog that binds to vitamin D receptors in skin cells to promote differentiation and reduce excessive proliferation in psoriasis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vectical Ointment TARGET	Vectical Ointment	University of California, San Francisco	marketed	Vitamin D3 analog	Vitamin D receptor (VDR)
Calcijex	CALCITRIOL	Esjay Pharma	marketed	Vitamin D3 Analog [EPC]	Vitamin D3 receptor	1978-01-01
Calcitriol capsules	Calcitriol capsules	Indonesia University	marketed	Vitamin D3 Analog [EPC]
calcipotriol hydrate [Daivonex]	calcipotriol hydrate [Daivonex]	Hoffmann-La Roche	marketed	Vitamin D3 analog	Vitamin D receptor (VDR)
Daivonex® scalp solution	Daivonex® scalp solution	LEO Pharma	marketed	Vitamin D3 analogue	Vitamin D receptor (VDR)
Calcipotriene Foam	Calcipotriene Foam	Stiefel, a GSK Company	phase 3	Vitamin D3 analog	Vitamin D receptor (VDR)
Calcipotriol BDP gel	Calcipotriol BDP gel	LEO Pharma	phase 3	Vitamin D3 analog / Corticosteroid combination	Vitamin D receptor (VDR); Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin D3 analog class)

LEO Pharma · 2 drugs in this class
Hoffmann-La Roche · 1 drug in this class
Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
Stiefel, a GSK Company · 1 drug in this class
University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vectical Ointment — Competitive Intelligence Brief. https://druglandscape.com/ci/vectical-ointment. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab